Overview

Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients

Status:
Not yet recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

It is a randomized phase II clinical study, unicentre aimed to evaluate the tolerability, safety and efficacy of 18-Methoxyoronaridine as a candidate of tegumentary leishmaniasis treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Infan Industria Quimica Farmaceutica Nacional

Collaborator:

Evandro Chagas National Institute of Infectious Disease

Treatments:

Ibogaine
Meglumine Antimoniate